In conversation with... Arndt Vogel

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

Episode metadata supplied by the publisher feed · Published Jul 31, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Arndt Vogel

0:00 18:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 18 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on July 31, 2024.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!